WellSIM BioMedical Technologies Revenue and Competitors
Estimated Revenue & Valuation
- WellSIM BioMedical Technologies's estimated annual revenue is currently $1.4M per year.
- WellSIM BioMedical Technologies's estimated revenue per employee is $155,000
Employee Data
- WellSIM BioMedical Technologies has 9 Employees.
- WellSIM BioMedical Technologies grew their employee count by 0% last year.
WellSIM BioMedical Technologies's People
Name | Title | Email/Phone |
---|
WellSIM BioMedical Technologies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is WellSIM BioMedical Technologies?
WellSIM Biotech focuses on diagnostic technologies for non-invasive liquid biopsy testing through enrichment and interrogation of extracellular vesicles (EVs) from bodily fluids such as plasma, urine, and saliva. The discovery of novel cancer biomarkers from EVs is increasingly enabling early diagnosis, prognosis, and therapeutics. WellSIM is dedicating to this growing trend and help transform the practice of medicine. Our goal is to develop life science tools for EV research and precision medicine, covering exosome isolation and enrichment, imaging and quantitation, single-exosome proteomics and genomics.
keywords:N/AN/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.7M | 9 | 0% | N/A |
#2 | $0.9M | 9 | -10% | N/A |
#3 | $0.1M | 9 | -18% | N/A |
#4 | $0.9M | 9 | 13% | N/A |
#5 | $0.7M | 9 | N/A | N/A |